Verily Health, Inc.

Verily Health, Inc. (formerly Verily Life Sciences LLC & Google Life Sciences) is a health care technology company founded in 2015 by Andrew Conrad, Brian Otis, and Jessica Mega. The company is headquartered in Dallas, Texas, having relocated from South San Francisco in 2024. Originally established as Google Life Sciences within the Google X division, it transitioned into an independent subsidiary of Alphabet Inc. in 2015. In March 2026, the company underwent a significant corporate restructuring, changing its legal name to Verily Health, Inc. and transitioning from an LLC to a corporation following a $300 million investment round. This shift resulted in Alphabet becoming a significant minority investor and relinquishing its controlling stake, effectively establishing the company as an independent entity, with a shift from heavy R&D toward commercializing the "Verily Pre" platform and "Lightpath" for chronic disease.

Business/Product Breakdown

Verily Health, Inc. operates an AI-native precision health platform designed to bridge the gap between clinical research and patient care. The company's primary technology infrastructure, the "Pre" platform, serves as an end-to-end ecosystem that harmonizes fragmented health data to provide actionable insights for biopharmaceutical companies, health systems, and researchers. Its clinical evidence generation solutions facilitate decentralized and hybrid clinical trials, utilizing tools like the Project Baseline platform to engage diverse populations and streamline data collection. In the area of care delivery, the company provides virtual care solutions and personalized management programs for chronic conditions, such as diabetes and hypertension, through its Onduo brand. The company's portfolio also includes health-tracking hardware and diagnostic tools, supported by recent commercial partnerships with Samsung for biomarker development and Salesforce for data integration. By leveraging data science and artificial intelligence, the company aims to transition healthcare from a reactive model to a proactive, personalized, and precise system.